title: Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
abstract: OBJECTIVE
  Biphasic insulin aspart 30 allows fewer daily injections versus basal-bolus insulin regimens, which may improve adherence and treatment outcome. This sub-analysis of the observational A1chieve study assessed clinical safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes previously receiving basal-bolus insulin regimens.
  
  
  METHODS
  A1chieve was an international, open-label, 24-week study in people with type 2 diabetes starting/switching to biphasic insulin aspart 30, insulin detemir or insulin aspart. This sub-analysis assessed patients switching from insulin glargine- or neutral protamine Hagedorn insulin-based basal-bolus insulin regimens to biphasic insulin aspart 30.
  
  
  RESULTS
  1024 patients were included. At 24 weeks, glycated haemoglobin and fasting plasma glucose were significantly reduced from baseline in both cohorts (all p<0.001). The proportion reporting any hypoglycaemia, major hypoglycaemia or nocturnal hypoglycaemia was significantly reduced after 24 weeks (all p<0.05). No serious adverse drug reactions were reported. Both cohorts had significantly improved health-related quality of life (HRQoL; p<0.001).
  
  
  CONCLUSIONS
  24 weeks after switching from basal-bolus insulin regimens to biphasic insulin aspart 30, glycaemic control and HRQoL were significantly improved, and hypoglycaemia was significantly reduced. This suggests that people with type 2 diabetes inadequately controlled on basal-bolus insulin regimens can consider biphasic insulin aspart 30.
authors: Centro de Atención Integral en Diabetes, Endocrinología y Metabolismo, Chacabuco, Province of Buenos Aires, Argentina.
authors: Guillermo
authors: G
authors: Dieuzeide
authors: Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
authors: Lee-Ming
authors: LM
authors: Chuang
authors: Medicine Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
authors: Abdulrahman
authors: A
authors: Almaghamsi
authors: Department of Endocrinology, First Moscow State Medical University, Moscow, Russia.
authors: Alexey
authors: A
authors: Zilov
authors: Novo Nordisk Region International Operations A/S, Zurich, Switzerland. Electronic address: jwch@novonordisk.com.
authors: Jian-Wen
authors: JW
authors: Chen
authors: Endocrine Service at the University Hospital "Dr José E González" School of Medicine UANL, Monterrey, Mexico.
authors: Fernando J
authors: FJ
authors: Lavalle-González
mesh_terms: D000328:Adult; D000352:Africa, Northern; D000368:Aged; D001208:Asia; D015415:Biomarkers / Q000097:blood; D061265:Biphasic Insulins / Q000008:administration & dosage* / Q000009:adverse effects; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D004334:Drug Administration Schedule; D057915:Drug Substitution; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007267:Injections; D061267:Insulin Aspart / Q000008:administration & dosage* / Q000009:adverse effects; D000069036:Insulin Glargine; D007336:Insulin, Isophane / Q000008:administration & dosage* / Q000009:adverse effects; D049528:Insulin, Long-Acting / Q000008:administration & dosage; D007843:Latin America; D008297:Male; D008875:Middle Aged; D008877:Middle East; D011788:Quality of Life; D012426:Russia; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D061265:Biphasic Insulins; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D061267:Insulin Aspart; D000069036:Insulin Glargine; D007336:Insulin, Isophane; D049528:Insulin, Long-Acting; C517652:hemoglobin A1c protein, human; C557564:insulin aspart, insulin aspart protamine drug combination 30:70
keywords: A(1)chieve; Basal-bolus insulin regimen; Biphasic insulin aspart; Type 2 diabetes